The effect of information technology (IT) material weaknesses in internal control on chief financial officer (CFO) turnover
Journal of Corporate Accounting & Finance · 2021-10 · 32 (4) · 45-53
DOI: 10.1002/jcaf.22508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Corporate Accounting & Finance, online erschienen am 08.07.2021. Verfasst von Kazeem O. Akinyele. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
This study examines the relationship between CFO turnover and adverse SOX Section 404 opinions relating to IT material weaknesses over a 4‐year period after implementation of SOX 404 requirements. Prior research has shown that IT material weaknesses in internal controls are associated with higher audit fees than are other types of material weaknesses. Prior research also suggests an association between poor financial performance and CFO turnover. The results of this study show that companies with IT related material weaknesses are more likely to have more CFO turnover relative to companies with non‐IT related material weaknesses. These results contribute to the stream of research exploring the implications of IT material weaknesses in organizations.
Zitieren
APA
Akinyele, K. O. (2021). The effect of information technology (IT) material weaknesses in internal control on chief financial officer (CFO) turnover. Journal of Corporate Accounting & Finance, 32(4), 45-53. https://doi.org/10.1002/jcaf.22508
Vancouver
Akinyele KO. The effect of information technology (IT) material weaknesses in internal control on chief financial officer (CFO) turnover. Journal of Corporate Accounting & Finance. 2021;32(4):45-53. doi:10.1002/jcaf.22508
BibTeX
@article{Akinyele2021,
author = {Akinyele, Kazeem O.},
title = {The effect of information technology (IT) material weaknesses in internal control on chief financial officer (CFO) turnover},
journal = {Journal of Corporate Accounting & Finance},
year = {2021},
volume = {32},
number = {4},
pages = {45--53},
doi = {10.1002/jcaf.22508}
}
EUVIMED